Anbio Biotechnology Class... (NNNN)
| Bid | 7.36 |
| Market Cap | 324.79M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | 0.03 |
| PE Ratio (ttm) | 246.67 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 7.64 |
| Volume | 143,528 |
| Avg. Volume (20D) | 276,237 |
| Open | 7.40 |
| Previous Close | 7.52 |
| Day's Range | 7.32 - 7.76 |
| 52-Week Range | 5.18 - 7.80 |
| Beta | 0.00 |
About NNNN
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves o...
1 month ago · seekingalpha.com
U.S. IPO Weekly Recap: IPO Calendar Slows Down With Small ListingsThe calendar slowed down this past week, with only small listings in the US. There was one sizable filing this past week - AIRO Group Holdings. No IPOs are currently scheduled to list in the week ahea...
2 months ago · seekingalpha.com
U.S. IPO Weekly Recap: 2 Microcaps List As More Small Issuers File For ListingsTwo small IPOs listed this week - INLIF and OneConstruction Group. Five issuers and two SPACs submitted initial filings this week. The 2025 IPO market is here, and while there are a few small deals on...
2 months ago · seekingalpha.com
Anbio Biotechnology Pursues U.S. IPO For Its IVD Products LaunchAnbio Biotechnology plans to raise $8.8 million in an IPO to commercialize its in vitro diagnostics products amid market risks. The company has experienced fluctuating revenue and profitability, with ...